Publication | Closed Access

Phase II prospective study of the efficacy of gefitinib for the treatment of stage III/IV non-small cell lung cancer with EGFR mutations, irrespective of previous chemotherapy

OncologyPrevious ChemotherapyPathologyBronchial NeoplasmCancer TreatmentEgfr MutationsMedicineRadiation OncologyLung Cancer